Heart failure treatment has changed more in the past decade than in the previous thirty years combined. A wave of drugs originally designed for other conditions, along with entirely new classes of therapy, have reshaped what doctors can offer people whose hearts cannot pump or fill effectively. SGLT2 inhibitors, once diabetes drugs, now form part of the standard regimen across virtually all types of heart failure. Semaglutide, a weight-loss medication, has shown striking benefits in a specific subset of heart failure patients. And further out on the horizon, gene therapies and cardiac myosin activators are being tested in clinical trials that could change the game again.
The Modern Foundation and How It Expanded
For years, heart failure with reduced pumping strength was managed with a combination of three drug classes: drugs that block the renin-angiotensin system, beta-blockers, and mineralocorticoid receptor antagonists. The past several years added a fourth pillar, creating what cardiologists now call “quadruple therapy.” An analysis of real-world hospitalized patients found that roughly 46% could receive all four foundational drugs at discharge, a figure that highlights both the feasibility and the gap in implementation.1PubMed Central. Eligibility for the 4 Pharmacological Pillars in Heart Failure With Reduced Ejection Fraction at Discharge The two newest pillars, SGLT2 inhibitors and the angiotensin receptor-neprilysin inhibitor sacubitril-valsartan, represent the biggest therapeutic advances in recent memory and now anchor the standard of care.
SGLT2 Inhibitors Across the Spectrum
Sodium-glucose cotransporter 2 inhibitors, drugs like dapagliflozin and empagliflozin, were developed to lower blood sugar in type 2 diabetes. Their cardiovascular benefits, first noticed in diabetes trials, turned out to be so consistent that they are now recommended for heart failure regardless of whether the patient has diabetes. They have become the latest addition to guideline-directed therapy across the full spectrum of heart failure, from reduced to preserved pumping function.2PubMed Central. SGLT-2 Inhibitors in Heart Failure: A Review of Current Evidence
Clinical trials have shown that hospitalization for heart failure drops by about a third with SGLT2 inhibitors, and that benefit holds regardless of patient characteristics like age, sex, or diabetes status.3PubMed. Mechanisms and Evidence for Heart Failure Benefits from SGLT2 Inhibitors How they accomplish this is still being worked out. The leading theories involve several overlapping effects: they promote the body’s excretion of sodium and water, which reduces the volume overload that strains a failing heart; they improve blood vessel function and lower the resistance the heart pumps against; and they shift the heart’s energy metabolism toward more efficient fuel sources like ketone bodies. There is also evidence that they may reduce inflammation and protect against harmful cardiac remodeling.4PubMed. SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review
The breadth of that mechanistic profile is part of what makes these drugs so unusual. Most heart failure medications target one pathway. SGLT2 inhibitors seem to touch several at once, which may explain why their benefits extend to patients with preserved pumping function, a group that historically had few effective treatments.
Sacubitril-Valsartan and Dual-Action Inhibition
Sacubitril-valsartan was the first drug in a class called angiotensin receptor-neprilysin inhibitors, or ARNIs. It works by combining two mechanisms in a single pill: blocking the angiotensin receptor (the same target older drugs like losartan hit) and inhibiting neprilysin, an enzyme that breaks down beneficial natriuretic peptides.5PubMed Central. Sacubitril-Valsartan, Clinical Benefits and Related Mechanisms of Action in Heart Failure With Reduced Ejection Fraction. A Review By letting those peptides stick around longer, the drug promotes blood vessel relaxation, sodium excretion, and reduced scarring in the heart. In the landmark trial that led to its approval, sacubitril-valsartan outperformed the older standard drug enalapril in reducing death and hospitalization for patients with reduced ejection fraction, cementing its role as the preferred agent over older ACE inhibitors in that population.
Semaglutide for Heart Failure With Obesity
One of the most talked-about developments in heart failure is the arrival of GLP-1 receptor agonists, particularly semaglutide, better known for weight loss and diabetes control. In a trial of patients who had heart failure with preserved ejection fraction and obesity, semaglutide led to meaningful improvements in symptoms and physical function compared to placebo. Patients on semaglutide walked further in a six-minute walk test (an improvement of about 20 meters more than placebo) and reported substantially better quality of life, while also losing considerably more weight.6PubMed. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity
A follow-up analysis confirmed that these benefits held across different obesity categories. Patients who lost more weight tended to see larger improvements in symptoms and reductions in a marker of systemic inflammation called CRP.7Nature Medicine. Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial This is significant because heart failure with preserved ejection fraction in the setting of obesity is extremely common, and until recently there was very little to offer beyond diuretics and lifestyle changes. It remains to be seen whether semaglutide reduces hard endpoints like death or hospitalization in this group, but the symptomatic improvements are already shifting clinical conversations.
Vericiguat and the Nitric Oxide Pathway
Vericiguat targets a different pathway entirely. In heart failure, the signaling chain that relies on nitric oxide to relax blood vessels and protect the heart becomes impaired. Previous attempts to fix this using nitric oxide donors or other indirect approaches produced mixed results. Vericiguat works by directly stimulating soluble guanylate cyclase, the enzyme in the middle of the pathway, and it does so in a way that complements rather than duplicates existing therapies.8PubMed. Vericiguat for the treatment of heart failure: mechanism of action and pharmacological properties compared with other emerging therapeutic options Approved after a trial in patients with worsening heart failure who were already on standard treatments, vericiguat fills a niche for people whose disease progresses despite maximal conventional therapy.9PubMed Central. Vericiguat, a novel sGC stimulator: Mechanism of action, clinical, and translational science
Finerenone and Next-Generation Aldosterone Blockers
Spironolactone and eplerenone, the traditional mineralocorticoid receptor antagonists, have been heart failure staples for years but come with side effects, most notoriously elevated potassium levels, that limit how aggressively doctors can dose them. Finerenone is a newer, non-steroidal version of these drugs. It was initially studied in patients with chronic kidney disease and type 2 diabetes, where it reduced both kidney and cardiovascular outcomes. The cardiovascular composite, which included death from heart causes, heart attack, stroke, and hospitalization for heart failure, occurred less frequently in the finerenone group.10PubMed Central. The non-steroidal mineralocorticoid receptor antagonist finerenone and heart failure with preserved ejection fraction Research is now exploring finerenone’s potential specifically in heart failure with preserved ejection fraction, where the older steroidal agents have shown limited benefit.
A related practical advance involves potassium binders, drugs that lower potassium levels in the gut. A meta-analysis found that these binders significantly improved the ability to get patients on target doses of mineralocorticoid receptor antagonists and cut the rate of high-potassium episodes by more than half.11PubMed Central. The efficacy and safety of new potassium binders on renin–angiotensin–aldosterone system inhibitor optimization in heart failure patients: a systematic review and meta‐analysis This might sound like a minor supporting role, but in practice, the inability to tolerate adequate doses of proven drugs is one of the biggest barriers in heart failure management. Potassium binders may indirectly save lives by enabling the medications that directly do.
Why the Two Main Types of Heart Failure Need Different Drugs
Heart failure with reduced ejection fraction and heart failure with preserved ejection fraction look similar from the outside, fatigue, shortness of breath, fluid buildup, but they arise from fundamentally different biology. A large multi-omics study recently identified 70 potential drug targets for the reduced type and 10 for the preserved type, and none of them overlapped.12Nature Cardiovascular Research. Large-scale multi-omics identifies drug targets for heart failure with reduced and preserved ejection fraction That finding reinforces what clinicians have long suspected: the two subtypes are distinct diseases sharing a final common pathway, and they need distinct therapies.13PubMed Central. Drug Targets for Heart Failure with Preserved Ejection Fraction: A Mechanistic Approach and Review of Contemporary Clinical Trials The practical implication is that breakthroughs in one type do not automatically carry over to the other. Semaglutide’s benefits, for instance, were demonstrated in preserved-type patients with obesity, while cardiac myosin activators are being tested specifically in the reduced type.
Therapies Still in the Pipeline
Several approaches are earlier in development but could change heart failure treatment in the coming years.
Cardiac Myosin Activators
Omecamtiv mecarbil is a first-in-class drug that works at the level of the heart muscle protein myosin itself. Rather than altering neurohormonal signaling or fluid balance, it directly makes each heartbeat more efficient by increasing the force and duration of the cardiac muscle’s contraction cycle.14The Lancet. Effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial This mechanism is completely different from anything else in the heart failure toolkit. Larger trials have shown modest reductions in heart failure events, and the drug’s regulatory path is still playing out, but the concept of directly targeting the contractile machinery is one of the more genuinely novel ideas in the field.
Apelin Receptor Agonists
The apelin system is a signaling pathway that promotes cardiac output and blood vessel dilation. Two synthetic apelin receptor agonists, BMS-986224 and AMG 986, have shown promise in early-stage research. In animal models of heart disease, oral dosing of BMS-986224 produced a sustained increase in cardiac output with a profile distinct from conventional drugs like enalapril.15PubMed Central. In Vitro and In Vivo Evaluation of a Small-Molecule APJ (Apelin Receptor) Agonist, BMS-986224, as a Potential Treatment for Heart Failure AMG 986 has entered first-in-human testing, where it improved cardiac contractility in early results without harmful changes to blood pressure or heart rate.16PubMed. A First-in-Human Study of AMG 986, a Novel Apelin Receptor Agonist, in Healthy Subjects and Heart Failure Patients These are still early days, but the idea of a drug that boosts heart output through a completely new receptor system is attracting serious investment.
Gene and RNA Therapies
Gene therapy for heart failure has had a rough history. The most advanced program, which delivered the gene for a calcium-handling pump called SERCA2a directly into the heart via a viral vector, progressed to a phase 2b trial with roughly 250 patients but failed to show benefit. Analysis revealed that fewer than 1% of heart muscle cells were actually reached by the therapy, so three current trials are testing higher doses to see if better delivery changes the outcome.17Cardiovascular Research. Gene therapy in cardiac and vascular diseases: a review of approaches to treat genetic and common cardiovascular diseases with novel gene-based therapeutics Other clinical trials are already underway targeting different molecular players in calcium signaling, including PP1 and CaMKII, two proteins that regulate how heart cells contract and relax.18PubMed Central. RNA Therapeutics in Heart Failure The field learned from the SERCA2a experience that the delivery problem, getting enough of the therapeutic payload into enough heart cells, is the central engineering challenge. Until that is solved, the biology will remain promising but the clinical results may lag behind.
Cardiac Regeneration and Stem Cell Approaches
The ultimate dream in heart failure therapy is to replace lost heart muscle rather than just manage what remains. The adult heart has almost no natural capacity to regenerate, so researchers have explored stem cell transplants, tissue engineering, and in-vivo reprogramming to try to rebuild damaged areas. Mesenchymal stem cell therapy has shown the most encouraging preclinical results, with studies demonstrating reduced scarring, new blood vessel growth, and some improvement in heart structure and function.19PubMed Central. Rebuilding the Damaged Heart: Mesenchymal Stem Cells, Cell-Based Therapy, and Engineered Heart Tissue
But results have been inconsistent. Many studies show initial improvement that fades over time, and the mechanisms behind whatever benefit exists remain poorly understood. Transplanted cells need to survive, integrate electrically with the existing heart tissue, receive blood supply, and avoid immune rejection, a list of hurdles that no approach has fully cleared.20PubMed Central. Stem cells for cardiac repair: an introduction Newer work with three-dimensional scaffolds and bioprinted heart tissue, using stem cell-derived heart muscle cells placed on structures that mimic the heart’s architecture, aims to improve cell survival and organization after transplantation.21Experimental & Molecular Medicine. Cardiac repair and regeneration: cell therapy, in vivo reprogramming, and the promise of extracellular vesicles Cardiac regeneration remains a decade or more from clinical reality, but the incremental progress is real.
Intravenous Iron for Exercise Capacity
Iron deficiency is common in heart failure patients, even when they are not technically anemic, and it worsens symptoms and exercise tolerance. A trial of intravenous ferric carboxymaltose found that treated patients maintained their exercise capacity over 24 weeks while the control group declined. Patients who received iron also reported better overall well-being and improved functional class.22PubMed Central. Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Chronic Heart Failure and Iron Deficiency Iron infusions are not a new drug in the traditional sense, but their integration into heart failure guidelines represents a shift in thinking: treating iron deficiency as a distinct, treatable contributor to symptoms rather than a lab abnormality to monitor passively.
Sex Differences in How Treatments Work
Women and men differ in heart size, blood vessel stiffness, body composition, and dominant hormones, all of which can influence how heart failure drugs behave in the body. Women tend to develop heart failure with preserved ejection fraction more often, while men are more likely to have the reduced type. There are documented differences in how women and men metabolize certain heart failure medications, which means that the dose needed for the same clinical effect can vary between sexes, and side effects at identical doses can differ as well.23PubMed Central. Sex differences in diagnosis and treatment of heart failure: toward precision medicine
A large meta-analysis of 70 randomized trials that reported outcomes separately for women and men, however, found no overall difference in how effective heart failure drugs were between the sexes.24European Heart Journal. Sex differences in effects of pharmacological treatment of heart failure: a meta-analysis and meta-regression of randomized controlled trials The drugs work in both groups; the concern is more about dose optimization and side-effect profiles than about whether to use them at all. Researchers have called for trials designed to detect sex-specific optimal dosing, arguing that a one-size-fits-all approach may leave some patients undertreated and others overexposed to side effects.25Nature Reviews Cardiology. Sex-related similarities and differences in responses to heart failure therapies
Biomarkers and Tracking Treatment Response
Natriuretic peptides, blood proteins released when the heart is under strain, are the most established biomarkers in heart failure. They are useful for diagnosis and prognosis, but their role in guiding treatment adjustments is less clear. An analysis across multiple trials found that changes in natriuretic peptide levels during treatment were strongly correlated with later hospitalization for heart failure, especially in more recent trials.26PubMed. Natriuretic Peptides as Biomarkers of Treatment Response in Clinical Trials of Heart Failure However, those same changes did not reliably predict differences in overall death rates. Newer biomarkers that reflect inflammation, fibrosis, and cardiac injury are being studied, but none have proven effective enough to guide therapy decisions on their own.27PubMed. Do Heart Failure Biomarkers Influence Heart Failure Treatment Response? The gap between biomarker promise and clinical utility is one area where the field oversells what is currently possible.
Precision Medicine and Machine Learning
The broader vision behind many of these developments is to match the right treatment to the right patient, an approach sometimes called precision cardiology. Machine learning tools are being developed to subcategorize heart failure patients beyond the simple reduced-versus-preserved split, potentially identifying clusters of patients who respond best to specific drugs. Advances in genomics could eventually allow clinicians to understand an individual’s genetic predisposition to certain types of heart failure and choose therapies accordingly.28Nature Reviews Cardiology. Towards precision medicine in heart failure This is genuinely exciting but still largely aspirational. In day-to-day cardiology, treatment decisions remain protocol-driven rather than genotype-driven, and the most impactful near-term improvement may be simply getting more patients on the drugs already proven to work.
Protecting the Heart From Cancer Treatment
An area gaining attention is preventing heart failure caused by cancer chemotherapy. Drugs like doxorubicin and trastuzumab, used against breast cancer and other malignancies, can severely damage the heart. In a mouse study, prophylactic treatment with empagliflozin (an SGLT2 inhibitor) given alongside chemotherapy preserved heart pumping function far better than untreated controls, where ejection fraction dropped from about 75% to 40%. Empagliflozin maintained it near 66%, and combining it with the ACE inhibitor perindopril produced similar protection.29PubMed Central. The Cardioprotective Effects of Empagliflozin with and Without ACE Inhibition in Chemotherapy-Induced Cardiotoxicity These are animal data, but they align with an emerging clinical interest in using existing heart failure drugs to prevent chemotherapy-related heart damage before it starts, rather than scrambling to treat it afterward.
The Cost Problem
Breakthroughs matter only if patients can access them. Newer heart failure medications, particularly sacubitril-valsartan and SGLT2 inhibitors, carry substantially higher out-of-pocket costs than older generic drugs.30PubMed Central. Economic Issues in Heart Failure in the United States High co-pays push patients toward poor adherence or abandonment of prescriptions entirely. Financial toxicity, the downstream harm that medication costs inflict on a patient’s economic stability, is increasingly recognized as a clinical problem in its own right.31PubMed Central. Financial Toxicity of Medical Management of Heart Failure: JACC Review Topic of the Week Strategies being explored include systemic changes to reduce cost sharing, better insurance coverage, financial navigation services, discount programs, and policies aimed at lowering drug prices. Cost-effectiveness analyses can help identify whether a drug’s clinical benefit justifies its sticker price at launch and as more real-world data accumulates.32PubMed Central. The Price of Progress: Cost, Access, and Adoption of Novel Cardiovascular Drugs in Clinical Practice
Pediatric Heart Failure and Ivabradine
Heart failure drug development has historically focused on adults, leaving children with limited options, many of which are used off-label. Ivabradine, a drug that slows heart rate by a different mechanism than beta-blockers, was tested in children with dilated cardiomyopathy and chronic heart failure. It safely lowered resting heart rate, improved the heart’s pumping ability, and showed favorable trends in clinical status and quality of life, though dosing required careful individual adjustment because the drug’s effect on heart rate varied substantially between children.33PubMed. Ivabradine in Children With Dilated Cardiomyopathy and Symptomatic Chronic Heart Failure Pediatric heart failure remains a niche within the field, but studies like this one are slowly building an evidence base that could bring guideline-level therapy to a population that has long been treated by extrapolation from adult data.